Bristol-Myers Squibb Company (NYSE:BMY) has signed an option agreement to acquire Galecto Biotech of Denmark and get access to its early-stage investigational idiopathic pulmonary fibrosis treatment. Bristol-Myers Squibb Company (NYSE:BMY) belongs to Healthcare sector. Its net profit margin is 16.90% and weekly performance is 7.98%. On last trading day company shares ended up $57.80. Bristol-Myers Squibb Company (NYSE:BMY) distance from 50-day simple moving average (SMA50) is 13.17%.

SunEdison Inc. (NYSE: SUNE) announced late last week it has been awarded 5 solar PV projects totaling 150 megawatts capacity in India. SunEdison or SunEdison affiliates will likely be the owners of the projects and will sell the electricity generated under Power Purchase Agreements (PPA’s) to various parties. “This is yet another milestone in the journey of SunEdison in India to build a strong pipeline of projects that will be developed and commissioned in the coming years,” said Pashupathy Gopalan, president Asia Pacific Operations. SunEdison, Inc. (NYSE:SUNE) shares advanced 2.56% in last trading session and ended the day at $20.01. SUNE Gross Margin is 5.10% and its return on assets is -15.20%. SunEdison, Inc. (NYSE:SUNE) quarterly performance is 3.30%.

Fairway Group Holdings Corp. (NASDAQ:FWM) has named Dorothy Carlow its Chief Merchandising Officer, effective Monday, Nov. 3, 2014. In this position, she will lead the merchandising team and Fairway’s buying and sales strategies, and work with the marketing department to expand and develop programs and promotions. On 03 November, Fairway Group Holdings Corp. (NASDAQ:FWM) shares moved down -1.67% and was closed at $2.94. FWM EPS growth in last 5 year was 0.00%. Fairway Group Holdings Corp. (NASDAQ:FWM) year to date (YTD) performance is -83.81%.

Celgene Corp. (NASDAQ: CELG) is a top biotech stock that saw some significant insider selling. A director at the company sold 100,000 shares of the stock at $102.90. The total liquidation came to a very tidy $10.3 million. The shares were trading at the end of Friday’s session at $107.09, so some pretty big money was left on the table. Celgene Corporation (NASDAQ:CELG) ended the last trading day at $107.41. Company weekly volatility is calculated as 2.20% and price to cash ratio as 12.50. Celgene Corporation (NASDAQ:CELG) showed a weekly performance of 4.18%.

Dynavax Technologies Corporation (NASDAQ:DVAX) on Oct. 13 announced initiation of a phase 1/2 clinical trial to assess the safety and preliminary efficacy of SD-101, an investigational Toll-like receptor (“TLR”) 9 agonist, in adults with untreated low-grade B-cell lymphoma. In this multicenter study (known as LYM-01), SD-101 is administered intratumorally in combination with localized low-dose radiation. The open-label, dose escalation and expansion design of LYM-01 is intended to accelerate dose optimization while simultaneously assessing the safety, tolerability and initial local and distant antitumor activity of SD-101. Dynavax Technologies Corporation (NASDAQ:DVAX) shares moved down -3.05% in last trading session and ended the day at $1.59. DVAX return on assets is -45.80%. Dynavax Technologies Corporation (NASDAQ:DVAX) quarterly performance is 5.30%.